MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) today welcomed the U.S. Food and Drug Administration's (FDA) newly released draft guidance on the development of non- opioid pain therapies, highlighting its potential to accelerate the company's lead program, Apitox, for chronic osteoarthritis pain. The draft guidance, entitled "Development of Non-Opioid Analgesics for Chronic Pain, Draft Guidance for Industry†, can be found here: https://www.fda.gov/regulatory-inform. ...

收入和利润 - 公司目前无任何营业收入[118][124] - 公司2025年第二季度净亏损266.22万美元，同比增长221.28万美元[115][122] - 2025年上半年净亏损306.46万美元，同比增长231.88万美元[123] - 净亏损扩大至3064590美元，同比增加2318754美元，主要因行政管理与研发费用增长[129] 成本和费用 - 2025年第二季度研发费用为65.18万美元，去年同期为0美元[117][119] - 2025年第二季度管理费用为201.21万美元，同比增长158.44万美元[117][120] - 2025年第二季度股权激励费用总计189.21万美元（研发43.86万+管理145.34万）[119][120] - 其他费用减少至36318美元，同比下降10035美元，主要因利息收入增加和认股权证负债公允价值变动产生约10000美元收益[127] - 利息支出增至61086美元，同比增加12055美元[127] 其他财务数据 - 2025年第二季度利息收入1.52万美元，同比增长1.47万美元[117][121] - 利息收入达15250美元，同比增加12572美元[127] - 认股权证负债公允价值变动产生9518美元收益[127] 现金流表现 - 经营活动现金流净流出3381409美元，同比增加2934254美元，主要受3064590美元净亏损影响[131] - 投资活动现金流净流出13368美元，去年同期为0美元[133] - 融资活动现金流净流入12126646美元，主要来自IPO发行普通股净收益11953046美元[134] - 现金及等价物净增加8731868美元，去年同期为净减少347155美元[131] 融资与资本活动 - 公司2025年5月IPO发行337.5万股，每股4美元，净融资1190万美元[116] - 现金储备预计可支持未来12个月运营[116] - 公司无营业收入且持续经营亏损，依赖股权/债务融资维持运营[130] 累计亏损 - 截至2025年6月30日累计亏损745.65万美元[116]

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________________to___________________________ Commission File Number: 001-42545 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or Apimeds Pharmaceuticals US, Inc. (Exact name of registrant as specifie ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42545 Apimeds Pharmaceuticals US, Inc. (Exact name of registrant as specified in its charter) Delaware 85-1099700 (State or other juris ...